JP2022527482A5 - - Google Patents
Info
- Publication number
- JP2022527482A5 JP2022527482A5 JP2021557790A JP2021557790A JP2022527482A5 JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5 JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025230741A JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166429 | 2019-03-29 | ||
| EP19166429.1 | 2019-03-29 | ||
| US201962833395P | 2019-04-12 | 2019-04-12 | |
| US62/833,395 | 2019-04-12 | ||
| PCT/EP2020/058814 WO2020201138A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Division JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527482A JP2022527482A (ja) | 2022-06-02 |
| JP2022527482A5 true JP2022527482A5 (https=) | 2024-07-24 |
| JPWO2020201138A5 JPWO2020201138A5 (https=) | 2024-07-24 |
Family
ID=69954076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557790A Pending JP2022527482A (ja) | 2019-03-29 | 2020-03-27 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220175768A1 (https=) |
| EP (2) | EP4548935A3 (https=) |
| JP (2) | JP2022527482A (https=) |
| KR (1) | KR20210143878A (https=) |
| CN (1) | CN113645975A (https=) |
| AU (1) | AU2020253054B2 (https=) |
| BR (1) | BR112021019203A2 (https=) |
| CA (1) | CA3130773A1 (https=) |
| IL (1) | IL286727A (https=) |
| JO (1) | JOP20210260A1 (https=) |
| MA (1) | MA55486A (https=) |
| MX (1) | MX2021011943A (https=) |
| PH (1) | PH12021552352A1 (https=) |
| SG (1) | SG11202109854RA (https=) |
| WO (1) | WO2020201138A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002980A (es) * | 2020-09-14 | 2023-06-06 | Janssen Pharmaceutica Nv | Terapias de combinación de inhibidores del fgfr. |
| KR20240019293A (ko) * | 2021-06-07 | 2024-02-14 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 습기 감응성 약학 조성물용 보호 코팅 |
| EP4415692A1 (en) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Erdafitinib formulations and systems for intravesical administration |
| CN119072311A (zh) | 2022-02-18 | 2024-12-03 | 塔里斯生物医药公司 | 用于膀胱内施用的厄达替尼制剂和渗透系统 |
| CN116106240B (zh) * | 2022-12-26 | 2025-11-07 | 华中农业大学 | 一种尿液酪氨酸检测体系、检测方法及检测试剂盒 |
| CN120731076A (zh) | 2023-02-13 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
| JP2026506041A (ja) | 2023-02-17 | 2026-02-20 | タリス バイオメディカル エルエルシー | 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-03-27 SG SG11202109854R patent/SG11202109854RA/en unknown
- 2020-03-27 US US17/598,985 patent/US20220175768A1/en active Pending
- 2020-03-27 EP EP24174999.3A patent/EP4548935A3/en active Pending
- 2020-03-27 AU AU2020253054A patent/AU2020253054B2/en active Active
- 2020-03-27 MA MA055486A patent/MA55486A/fr unknown
- 2020-03-27 CN CN202080026737.4A patent/CN113645975A/zh active Pending
- 2020-03-27 MX MX2021011943A patent/MX2021011943A/es unknown
- 2020-03-27 PH PH1/2021/552352A patent/PH12021552352A1/en unknown
- 2020-03-27 BR BR112021019203A patent/BR112021019203A2/pt unknown
- 2020-03-27 WO PCT/EP2020/058814 patent/WO2020201138A1/en not_active Ceased
- 2020-03-27 KR KR1020217034729A patent/KR20210143878A/ko not_active Ceased
- 2020-03-27 CA CA3130773A patent/CA3130773A1/en active Pending
- 2020-03-27 JP JP2021557790A patent/JP2022527482A/ja active Pending
- 2020-03-27 EP EP20713656.5A patent/EP3946340A1/en active Pending
-
2021
- 2021-09-23 JO JOP/2021/0260A patent/JOP20210260A1/ar unknown
- 2021-09-26 IL IL286727A patent/IL286727A/en unknown
-
2025
- 2025-12-04 JP JP2025230741A patent/JP2026048748A/ja active Pending